Dimerix (DXB) Investor Presentation summary

Strategic focus and clinical development

• Advancing therapies for inflammatory kidney diseases with unmet clinical needs, focusing on FSGS, a rare disease causing irreversible kidney damage and lacking approved treatments.

• Lead candidate DMX-200 is in a global Phase 3 trial (ACTION3) for FSGS, showing better performance than placebo in reducing proteinuria in interim analysis.

• DMX-200 disrupts inflammatory feedback in kidneys, reduces proteinuria, preserves podocytes, and demonstrates positive safety and efficacy in Phase 1/2 trials.

• FDA confirmed proteinuria as a primary endpoint for approval, with potential for accelerated approval based on ongoing data analysis.

• No approved therapies exist for FSGS; DMX-200 is the only inflammatory modulator in late-stage development.

Market opportunity and licensing

• FSGS has a global prevalence exceeding 200,000 cases, with significant growth potential as diagnosis rates rise.

• DMX-200 is licensed in key territories, with deals valued up to AU$1.4 billion in upfront and milestone payments plus royalties; over AU$65 million received to date.

• Additional licensing opportunities remain, especially in unlicensed regions such as Mainland China.

• Rare kidney disease drugs command high prices, with US examples around $9,900/month and European prices over $8,000/month.

Financials and corporate overview

• Market capitalization stands at $295 million, with a cash balance of $17 million as of March 2025, not including recent licensing payments.

• Substantial shareholders hold over 24% of issued capital; share price at $0.50 with strong liquidity.

• Potential catalysts in 2025 include FDA meetings, milestone payments, interim data, and new licensing deals.

• ESG principles are integrated into operations, reflecting a commitment to responsible and sustainable business practices.